Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

The clinical spectrum of rheumatoid arthritis (RA) presentation is heterogeneous, with wide variation in age of onset, degree of joint involvement and severity. Delayed rheumatological referral is associated with less favourable long-term outcomes. Multidisciplinary teamwork is key to the success of a holistic approach to patient care and addressing issues that are important to the person. Pharmacological treatment of early RA aims to optimally suppress the inflammatory component of the disease with an ideal treatment target of remission. The overarching aim of management of early RA is to achieve a quality of life that permits the individual to pursue normal work, domestic and social activity.

More information Original publication

DOI

10.7861/clinmed.2020-0727

Type

Journal article

Publication Date

2020-11-01T00:00:00+00:00

Volume

20

Pages

561 - 564

Total pages

3

Keywords

Rheumatoid arthritis, clinical assessment, disease-modifying anti-rheumatic drugs, methotrexate, treat-to-target, Antirheumatic Agents, Arthritis, Rheumatoid, Humans, Methotrexate, Quality of Life